Initially, we assessed the response of NCI-H69 SCLC cells to etoposide, p38MAPK inhibitor SB203580, and MK2 inhibitor MK2.III to check on the reproducibility and to establish the optimal concentration of p38MAPK and MK2 inhibitors to use. This evidence concerns the gene MAPKAPK2 and small cell lung carcinoma.